ACAD vs EXEL
ACADIA Pharmaceuticals Inc. vs Exelixis — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
| Metric | ACAD | EXEL |
|---|
| AI Score |
69
|
67
|
| Price |
$29.41
|
$51.30
|
| P/E Ratio |
13.07×
|
15.60×
|
| ROE |
31.9%
|
36.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
96.5%
|
| Debt / Equity |
0.06×
|
0.09×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
41.0
|
| Beta |
0.845
|
0.422
|
| Expected Upside |
—
|
+8.7%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus EXEL.
ACAD leads by 2 points.
ACAD scores 69/100 (Buy) versus EXEL at 67/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical